- Home
- AARD vs EAF Comparison
AARD vs EAF Comparison
Compare AARD & EAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- EAF
- Stock Information
- Founded
- AARD 2017
- EAF 1886
- Country
- AARD United States
- EAF United States
- Employees
- AARD N/A
- EAF N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- EAF Industrial Machinery/Components
- Sector
- AARD Health Care
- EAF Energy
- Exchange
- AARD Nasdaq
- EAF Nasdaq
- Market Cap
- AARD 242.9M
- EAF 265.9M
- IPO Year
- AARD 2025
- EAF 1995
- Fundamental
- Price
- AARD $8.59
- EAF $9.60
- Analyst Decision
- AARD Strong Buy
- EAF Hold
- Analyst Count
- AARD 5
- EAF 6
- Target Price
- AARD $32.60
- EAF $17.00
- AVG Volume (30 Days)
- AARD 77.3K
- EAF 202.2K
- Earning Date
- AARD 08-13-2025
- EAF 07-25-2025
- Dividend Yield
- AARD N/A
- EAF N/A
- EPS Growth
- AARD N/A
- EAF N/A
- EPS
- AARD N/A
- EAF N/A
- Revenue
- AARD N/A
- EAF $508,550,000.00
- Revenue This Year
- AARD N/A
- EAF N/A
- Revenue Next Year
- AARD N/A
- EAF $19.47
- P/E Ratio
- AARD N/A
- EAF N/A
- Revenue Growth
- AARD N/A
- EAF N/A
- 52 Week Low
- AARD $4.88
- EAF $5.50
- 52 Week High
- AARD $19.58
- EAF $25.30
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- EAF 38.29
- Support Level
- AARD N/A
- EAF $9.71
- Resistance Level
- AARD N/A
- EAF $10.75
- Average True Range (ATR)
- AARD 0.00
- EAF 1.03
- MACD
- AARD 0.00
- EAF -0.20
- Stochastic Oscillator
- AARD 0.00
- EAF 12.73
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.